Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 78

Results For "technology"

2044 News Found

Merck partners with California-based research group to study catalysis innovation through machine learning
News | June 02, 2023

Merck partners with California-based research group to study catalysis innovation through machine learning

Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques


Laurus Labs to increase stake in ImmunoACT to 33.86%
News | June 01, 2023

Laurus Labs to increase stake in ImmunoACT to 33.86%

This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19


Concept Medical gets 4th IDE approval from USFDA
Drug Approval | May 31, 2023

Concept Medical gets 4th IDE approval from USFDA

For the treatment of Superficial Femoral Artery


Hikal posts FY23 PAT at Rs. 36 Cr
News | May 30, 2023

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22


Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22
News | May 29, 2023

Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22

Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239


Roquette, Beren Therapeutics join forces to advance cyclodextrin technologies
News | May 29, 2023

Roquette, Beren Therapeutics join forces to advance cyclodextrin technologies

Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.


Lupin Diagnostics Launches Satellite Laboratory in Vijayawada
News | May 26, 2023

Lupin Diagnostics Launches Satellite Laboratory in Vijayawada

Continues to Expand its Presence in South India


Agilent to appeal patent office decision on CRISPR gRNA patents
News | May 23, 2023

Agilent to appeal patent office decision on CRISPR gRNA patents

Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination


Freenome acquires global immunodiagnostics developer Oncimmune
News | May 23, 2023

Freenome acquires global immunodiagnostics developer Oncimmune

Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection